Literature DB >> 33687819

Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives.

Anastasia A Schegoleva1, Anna A Khozyainova1, Anton A Fedorov1, Tatiana S Gerashchenko1, Evgeny O Rodionov2, Evgeny B Topolnitsky3, Nikolay A Shefer4, Olga V Pankova5, Anastasia A Durova6, Marina V Zavyalova5,6, Vladimir M Perelmuter5, Evgeny V Denisov7.   

Abstract

Despite advances in diagnostics and therapy of non-small cell lung cancer (NSCLC), the problem of prognosis and prevention of tumor progression is still highly important. Even if NSCLC is diagnosed in the early stages, almost a quarter of patients develop relapse; most of them die from recurrent disease. A large number of different markers have been proposed to predict the risk of NSCLC progression; however, none of them are used in clinical practice. It is obvious that this situation is related to the economic and methodological complexity of the proposed markers and/or their insufficient efficiency due to a lack of effective study models and tumor heterogeneity. Another reason may be that potential markers are developed for NSCLC progression in general, which is represented by at least four pathogenetically-distinct processes: synchronous lymph node metastasis, local, regional, and distant recurrence. In this review, we summarize data from published literature on clinicopathological, genetic, and molecular factors associated with different types of NSCLC progression and emphasize challenges and approaches to developing prognostic factors. In conclusion, we highlight the importance of further studies to reveal molecular mechanisms of NSCLC progression and the need for differential analysis of markers of local, regional, and distant recurrences for disease prognosis. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  Non-small cell lung cancer; Progression; Recurrence; Metastasis; Marker

Mesh:

Substances:

Year:  2021        PMID: 33687819     DOI: 10.33594/000000340

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

Review 1.  Metastasis prevention: targeting causes and roots.

Authors:  A A Schegoleva; A A Khozyainova; T S Gerashchenko; L D Zhuikova; Evgeny V Denisov
Journal:  Clin Exp Metastasis       Date:  2022-03-26       Impact factor: 4.510

2.  CD2+ T-helper 17-like cells differentiated from a CD133+ subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma.

Authors:  Miaomiao Jia; Xianxian Jia; Dong Zhang; Wenxuan Liu; Shanyong Yi; Zhenhua Li; Bin Cong; Chunling Ma; Shujin Li; Jun Zhang
Journal:  Ann Transl Med       Date:  2021-04

3.  Design, Synthesis and Anti-Lung Cancer Evaluation of 1, 2, 3-Triazole Tethered Dihydroartemisinin-Isatin Hybrids.

Authors:  Haodong Hou; Bin Qu; Chen Su; Guihua Hou; Feng Gao
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

4.  MicroRNA-21 was a promising biomarker for lung carcinoma diagnosis: An update meta-analysis.

Authors:  Haiyan Wang; Jia Xu; Ling Ding
Journal:  Thorac Cancer       Date:  2021-11-27       Impact factor: 3.500

5.  To explore the prognostic value of spread through air spaces and develop a nomogram combined with spread through air spaces in lung squamous cell carcinoma.

Authors:  Hongyan Yu; Chengbin Lin; Xiaohan Chen; Zheng Wang; Weiyu Shen
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

6.  CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer.

Authors:  Yunha Nam; Chang-Min Choi; Young Soo Park; HyunA Jung; Hee Sang Hwang; Jae Cheol Lee; Jung Wook Lee; Jung Eun Lee; Jung Hee Kang; Byung Hun Jung; Wonjun Ji
Journal:  J Clin Med       Date:  2022-01-11       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.